Constitutively elevated NF-κB activity appears to be a common occurrence in ccRCC [15], [16], and disabling NF-κB signaling in these cells, for example, by using the proteasome inhibitor bortezomib, sensitizes them to multiple anti-neoplastic agents, including apoptosis by the cytokine TRAIL and oncolysis by the RNA virus encephalomyocarditis virus [17], [18], [19], [20], [21]. Here, NFKB1 is linked to nonpapillary renal cell carcinoma.